HIGHBuilt-inPipeline
bemnifosbuvir and ruzasvir regimen (HCV)
“10-K Item 1A: 'Our business is highly dependent on the success of our lead product candidate, the regimen of bemnifosbuvir and ruzasvir for the treatment of HCV infection.'”
AVIR · Concentration risk · 10-K extracted
Atea Pharmaceuticals (AVIR) concentration risks
Updated
The most significant concentration Atea Pharmaceuticals discloses is bemnifosbuvir and ruzasvir regimen (HCV), classified HIGH by disclosed size. Below: the full set from the latest 10-K — verbatim quotes, filing references, and a synthesis of what these exposures mean together.
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Source: Atea Pharmaceuticals’s SEC Form 10-K filed — view the filing on SEC EDGAR ↗
At a glance
Disclosed-size breakdown · 1 disclosed concentration
HIGH1
MEDIUM0
LOW0
Disclosed concentrations
Each card carries a disclosed-size chip (HIGH / MEDIUM / LOW — how large the exposure is as a share of revenue, not how dangerous it is) and a nature tag: Built-in(the company’s own model, geography, or products) or Outside party (an external customer, supplier, or distributor it relies on).
TrendMatrix Research · concentration synthesis
What these concentrations mean together
updated 2026-08-23Atea Pharmaceuticals' concentration risk is about as concentrated as a clinical-stage biotech's risk profile gets: the business is highly dependent on the success of its lead product candidate, the regimen of bemnifosbuvir and ruzasvir for the treatment of HCV infection. This is a structural concentration rather than a customer or supplier dependency — there is no revenue-generating product, customer base, or geographic mix to diversify against; the company's near-term and, by extension, long-term prospects rest on a single therapeutic program succeeding through trials and, eventually, commercialization. No percentage is disclosed in the cited claim because pre-commercial pipeline concentration isn't measured as a share of sales — it's measured in binary terms: the program works or it doesn't. That framing makes this a high-share exposure in every practical sense, even without a numeric weight attached, since the filing itself describes reliance on a single candidate rather than a portfolio. For investors, this means the investment case lives or dies with clinical and regulatory outcomes for one regimen, with no disclosed offsetting product, partnership, or revenue stream to soften a setback.
For the engine’s reasoning on AVIR’s current verdict — including which dimensions drove the score — see the per-dimension breakdown.
Industry peers · Biotechnology
Peer concentration profile
| Symbol | Name | HIGH | MEDIUM | LOW | Total |
|---|---|---|---|---|---|
| ACAD | ACADIA Pharmaceuticals Inc. | 2 | 0 | 0 | 2 |
| ABUS | Arbutus Biopharma Corporation | 1 | 1 | 0 | 2 |
| ABSI | Absci Corporation | 1 | 0 | 0 | 1 |
| AVIR● | Atea Pharmaceuticals, Inc. | 1 | 0 | 0 | 1 |
| ABCL | AbCellera Biologics Inc. | 0 | 0 | 0 | 0 |
| ACHV | Achieve Life Sciences, Inc. | 0 | 0 | 0 | 0 |
Concentration counts reflect items disclosed in each peer’s most recent 10-K; disclosed-size classification uses TrendMatrix’s internal 10-K extraction taxonomy.